title: Cancer testis antigen OY-TES-1: analysis of protein expression in ovarian cancer with tissue microarrays.
abstract: Revised manuscript accepted for publication March 5, Objectives: The purpose of this study was to determine the potential of cancer testis antigen OY-TES-1 as a vaccine for ovarian cancer (OC).
  
  
  METHODS
  A tissue microarray (TMA) containing 107 samples from OC tissues and 48 samples from OC adjacent tissues was analyzed by immunohistochemistry with the OY-TES-1 polyclonal antibody. The correlation between OY-TES-1 and clinic pathological traits of OC was statistically analyzed.
  
  
  RESULTS
  The expression of OY-TES-1 protein was found in 81% (87/107) of OC tissues and 56% (27/48) of OC adjacent tissues. The immunostaining intensity of OY-TES-1 in OC tissues was significantly higher than that in OC adjacent tissues tested (p = 0.040). OC adjacent tissues only demonstrated lower immunostaining intensity, whereas some of OC tissues presented higher immunostaining intensity and majority showed the heterogeneity of protein distribution. There was no statistically significant correlation found between OY-TES-1 expression and any other clinicopathological traits such as age, FIGO stage, pathological grade, and histological type.
  
  
  CONCLUSIONS
  OY-TES-1 was expressed in OC tissues with a high proportion, and some of OC tissues presented OY-TES-1 expression in high level vs OC adjacent tissues. OY-TES-1 could be an attractive target for immunotherapy for OC in the future.
authors.forename: R
authors.initials: R
authors.lastname: Fan
authors.forename: W
authors.initials: W
authors.lastname: Huang
authors.forename: B
authors.initials: B
authors.lastname: Luo
authors.forename: Q M
authors.initials: QM
authors.lastname: Zhang
authors.forename: S W
authors.initials: SW
authors.lastname: Xiao
authors.forename: X X
authors.initials: XX
authors.lastname: Xie
mesh_terms: D018262:Adenocarcinoma, Clear Cell / Q000378:metabolism* / Q000628:therapy; D000293:Adolescent; D000328:Adult; D000368:Aged; D019496:Cancer Vaccines; D002352:Carrier Proteins / Q000378:metabolism*; D002648:Child; D004407:Dysgerminoma / Q000378:metabolism* / Q000628:therapy; D005260:Female; D006801:Humans; D007150:Immunohistochemistry; D008875:Middle Aged; D058990:Molecular Targeted Therapy; D018297:Neoplasms, Cystic, Mucinous, and Serous / Q000378:metabolism* / Q000628:therapy; D010051:Ovarian Neoplasms / Q000378:metabolism* / Q000628:therapy; D046888:Tissue Array Analysis; D055815:Young Adult
chemical_list: C485651:ACRBP protein, human; D019496:Cancer Vaccines; D002352:Carrier Proteins